October 20, 2010 - The U.S. Food and Drug Administration (FDA) approved a new drug to help prevent stroke and blood clots in patients with abnormal heart rhythm (atrial fibrillation). Pradaxa (generic: dabigatran etexilate), by Boehringer Ingelheim Pharmaceuticals, will be available in 75 mg and 150 mg capsules.

October 20, 2010 – A new type of sterile marker for image-guided surgery has been launchd. The Threaded Spherz, by IZI Medical Products, are compatible with BrainLab systems and help surgeons optimize minimally invasive techniques.

October 19, 2010 – A new high-definition (HD) technology reduces blur created by respiration during positron emission tomography/computed tomography (PET/CT) studies. The Siemens HD Chest provides full HD lesion detection and improved standardized uptake value (SUV) quantification.

October 19, 2010 – Opto Circuits, an Indian company that designs, develops manufactures and markets healthcare equipment and interventional products, will acquire Cardiac Science. Cardiac Science manufactures ECG and stress test systems.

October 18, 2010 - A 54-year-old Italian man has become the first patient to surpass 1,000 days of support with an artificial heart while waiting for a matching donor heart. The patient was implanted with the SynCardia temporary Total Artificial Heart.

October 18, 2010 – Toronto General Hospital is the first Canadian medical center to implant a left-ventricular assist system (LVAS) as part of a study for patients awaiting a heart transplant. The Peter Munk Cardiac Centre used the DuraHeart LVAS, by Terumo Heart, as part of the SUSTAIN BTT study.


St. Jude Medical Inc. said it plans to acquire AGA Medical Holdings Inc. for about $1.3 billion. The purchase will expand St. Jude’s cardiac device offerings with a portfolio of transcatheter structural heart occluders.

October 15, 2010 – The U.S. Food and Drug Administration (FDA) has approved an abbreviated new drug application (ANDA) for a generic equivalent to Novartis’ Lotrel capsules.

October 15, 2010 – Medtronic has entered into a $268 million settlement relating to its Sprint Fidelis family of defibrillation leads.


October 15, 2010 – An investigational trial of Medtronic’s CoreValve transcatheter aortic valve has been approved by the U.S. Food and Drug Administration (FDA) today. The investigational device exemption (IDE) pivotal clinical trial will enroll more than 1,200 patients at 40 U.S. clinical sites.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now